News Test
Back
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus placerat sed quam id elementum. Ut ante mauris, scelerisque quis cursus et, mollis at turpis. Sed vel iaculis nunc, pharetra consequat enim. Fusce dignissim posuere pellentesque. Nunc viverra elementum sodales. Aenean vel augue neque. Praesent posuere neque eget fringilla feugiat. Donec sit amet dolor pulvinar, congue purus sit amet, ultricies elit. Nunc eu mollis mauris. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Maecenas vulputate lacinia tempus.
Testing News
Back
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus placerat sed quam id elementum. Ut ante mauris, scelerisque quis cursus et, mollis at turpis. Sed vel iaculis nunc, pharetra consequat enim. Fusce dignissim posuere pellentesque. Nunc viverra elementum sodales. Aenean vel augue neque. Praesent posuere neque eget fringilla feugiat. Donec sit amet dolor pulvinar, congue purus sit amet, ultricies elit. Nunc eu mollis mauris. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Maecenas vulputate lacinia tempus.
This is new
Back
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus placerat sed quam id elementum. Ut ante mauris, scelerisque quis cursus et, mollis at turpis. Sed vel iaculis nunc, pharetra consequat enim. Fusce dignissim posuere pellentesque. Nunc viverra elementum sodales. Aenean vel augue neque. Praesent posuere neque eget fringilla feugiat. Donec sit amet dolor pulvinar, congue purus sit amet, ultricies elit. Nunc eu mollis mauris. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae; Maecenas vulputate lacinia tempus.
Centers for Medicare and Medicaid Services on the Medicare Drug Price Negotiation Program
Back
[pdfjs-viewer url=”https://www.califesciences.org/wp-content/uploads/2023/04/CLS-Comments-to-CMS-on-MDPNP-Guidance.pdf” attachment_id=”14569″ viewer_width=100% viewer_height=800px fullscreen=true download=true print=true][pdfjs-viewer url=”https://www.califesciences.org/wp-content/uploads/2023/04/CLS-Comments-to-CMS-on-MDPNP-Guidance.pdf” attachment_id=”14569″ viewer_width=100% viewer_height=800px fullscreen=true download=true print=true]
CLS issues statement on mifepristone ruling
Back
“The decision by a federal judge in Texas earlier this week to revoke the approval of mifepristone, a drug approved over twenty years ago that is widely seen as safe and effective for multiple conditions and diseases, sets a dangerous precedence that upends FDA’s gold standard approval process on the safety and efficacy of medicine.
While we are relieved that a federal appeals court agreed last night to keep mifepristone on the market, we remain concerned that the court implemented restrictions on patient access until the full case is heard. If upheld, this ruling will undermine the entire life science industry’s ability to rely on the FDA pathways for developing new lifesaving products and therapies, creating even more uncertainty in an already high-risk industry.
This ruling also has long-term implications that go far beyond this one drug and takes this country on an extraordinarily dangerous path by having courts, not doctors and scientists, make decisions about the lifesaving treatments and cures available for patients and what should be science-based decision-making more broadly. It is our hope that when this case concludes, patients prevail, and the FDA’s decision-making authority will stand.” -CLS President & CEO Mike Guerra
Back
BioGENEius_Challenge_Poster_Guidelines
Back
CLSFAST-Application-2022A
Back